{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:42:59Z","timestamp":1788226979767,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["YQ2023H013"],"award-info":[{"award-number":["YQ2023H013"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04527-w","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:39:19Z","timestamp":1746178759000},"page":"3595-3610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["DNMT1 promotes bladder cancer progression and immune escape by inhibiting MYH11 expression by methylating its promoter"],"prefix":"10.1007","volume":"57","author":[{"given":"Shan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"4527_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57080749","author":"J Dobruch","year":"2021","unstructured":"Dobruch J, Oszczudlowski M (2021) Bladder Cancer: Current Challenges and Future Directions. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina57080749","journal-title":"Medicina (Kaunas)"},{"key":"4527_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L (2024) Advances in diagnosis and treatment of bladder cancer. BMJ 384:e076743. https:\/\/doi.org\/10.1136\/bmj-2023-076743","journal-title":"BMJ"},{"issue":"19","key":"4527_CR3","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD (2020) Bladder Cancer: A Review. JAMA 324(19):1980\u20131991. https:\/\/doi.org\/10.1001\/jama.2020.17598","journal-title":"JAMA"},{"issue":"2","key":"4527_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D (2021) Advances in bladder cancer biology and therapy. Nat Rev Cancer 21(2):104\u2013121. https:\/\/doi.org\/10.1038\/s41568-020-00313-1","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4527_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskjot","year":"2023","unstructured":"Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D (2023) Bladder cancer. Nat Rev Dis Primers 9(1):58. https:\/\/doi.org\/10.1038\/s41572-023-00468-9","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"4527_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","volume":"69","author":"PL Crispen","year":"2020","unstructured":"Crispen PL, Kusmartsev S (2020) Mechanisms of immune evasion in bladder cancer. Cancer Immunol Immunother 69(1):3\u201314. https:\/\/doi.org\/10.1007\/s00262-019-02443-4","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"4527_CR7","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/s41417-022-00506-w","volume":"29","author":"Q Liu","year":"2022","unstructured":"Liu Q, You B, Meng J, Huang CP, Dong G, Wang R, Chou F, Gao S, Chang C, Yeh S, Xu W (2022) Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2\/circ_0001005\/PD-L1 signaling. Cancer Gene Ther 29(12):1988\u20132000. https:\/\/doi.org\/10.1038\/s41417-022-00506-w","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"4527_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1161\/ATVBAHA.120.315107","volume":"41","author":"J Ruan","year":"2021","unstructured":"Ruan J, Zhang L, Hu D, Qu X, Yang F, Chen F, He X, Shen J, Dong K, Sweet M, Sanchez C, Li D, Shou W, Zhou J, Cai CL (2021) Novel Myh11 dual reporter mouse model provides definitive labeling and identification of smooth muscle cells-brief report. Arterioscler Thromb Vasc Biol 41(2):815\u2013821. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315107","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4527_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176311","author":"RB Day","year":"2023","unstructured":"Day RB, Hickman JA, Xu Z, Katerndahl CD, Ferraro F, Ramakrishnan SM, Erdmann-Gilmore P, Sprung RW, Mi Y, Townsend RR, Miller CA, Ley TJ (2023) Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia-initiating CBFB::MYH11 oncofusion protein. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI176311","journal-title":"J Clin Invest"},{"issue":"7","key":"4527_CR10","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41375-023-01926-9","volume":"37","author":"JL Diemer","year":"2023","unstructured":"Diemer JL, Yu K, Kelly M, Zhen T, Anderson S, Lopez G, Liu P (2023) Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing. Leukemia 37(7):1549\u20131553. https:\/\/doi.org\/10.1038\/s41375-023-01926-9","journal-title":"Leukemia"},{"key":"4527_CR11","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.2147\/OTT.S131386","volume":"10","author":"X Ning","year":"2017","unstructured":"Ning X, Deng Y (2017) Identification of key pathways and genes influencing prognosis in bladder urothelial carcinoma. Onco Targets Ther 10:1673\u20131686. https:\/\/doi.org\/10.2147\/OTT.S131386","journal-title":"Onco Targets Ther"},{"issue":"9","key":"4527_CR12","doi-asserted-by":"publisher","first-page":"15607","DOI":"10.1002\/jcp.28208","volume":"234","author":"J Hu","year":"2019","unstructured":"Hu J, Zhou L, Song Z, Xiong M, Zhang Y, Yang Y, Chen K, Chen Z (2019) The identification of new biomarkers for bladder cancer: a study based on TCGA and GEO datasets. J Cell Physiol 234(9):15607\u201315618. https:\/\/doi.org\/10.1002\/jcp.28208","journal-title":"J Cell Physiol"},{"key":"4527_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112657","author":"LK Larsen","year":"2019","unstructured":"Larsen LK, Lind GE, Guldberg P, Dahl C (2019) DNA-methylation-based detection of urological cancer in urine: overview of biomarkers and considerations on biomarker design, source of dna, and detection technologies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20112657","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4527_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202305275","volume":"11","author":"S Liang","year":"2024","unstructured":"Liang S, Liu M, Mu W, Gao T, Gao S, Fu S, Yuan S, Liu J, Liu Y, Jiang D, Zhang N (2024) Nano-regulator inhibits tumor immune escape via the \u201cTwo-Way Regulation\u201d epigenetic therapy strategy. Adv Sci (Weinh) 11(9):e2305275. https:\/\/doi.org\/10.1002\/advs.202305275","journal-title":"Adv Sci (Weinh)"},{"key":"4527_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107328","volume":"207","author":"T Chen","year":"2024","unstructured":"Chen T, Mahdadi S, Vidal M, Desbene-Finck S (2024) Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy. Pharmacol Res 207:107328. https:\/\/doi.org\/10.1016\/j.phrs.2024.107328","journal-title":"Pharmacol Res"},{"issue":"5","key":"4527_CR16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s13402-020-00526-4","volume":"43","author":"KK Wong","year":"2020","unstructured":"Wong KK (2020) DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications. Cell Oncol (Dordr) 43(5):779\u2013792. https:\/\/doi.org\/10.1007\/s13402-020-00526-4","journal-title":"Cell Oncol (Dordr)"},{"key":"4527_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118311","volume":"261","author":"P Liu","year":"2020","unstructured":"Liu P, Wu L, Chand H, Li C, Hu X, Li Y (2020) Silencing of miR-152 contributes to DNMT1-mediated CpG methylation of the PTEN promoter in bladder cancer. Life Sci 261:118311. https:\/\/doi.org\/10.1016\/j.lfs.2020.118311","journal-title":"Life Sci"},{"issue":"1","key":"4527_CR18","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1186\/s12885-021-08653-3","volume":"21","author":"J Wang","year":"2021","unstructured":"Wang J, Xu P, Hao Y, Yu T, Liu L, Song Y, Li Y (2021) Interaction between DNMT3B and MYH11 via hypermethylation regulates gastric cancer progression. BMC Cancer 21(1):914. https:\/\/doi.org\/10.1186\/s12885-021-08653-3","journal-title":"BMC Cancer"},{"issue":"1","key":"4527_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s13046-023-02900-0","volume":"42","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Yu Y, Zhang Z, Li D, Liang Z, Wang L, Chen Y, Liang Y, Niu H (2023) Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1. J Exp Clin Cancer Res 42(1):316. https:\/\/doi.org\/10.1186\/s13046-023-02900-0","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4527_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12967-024-05099-6","volume":"22","author":"L Li","year":"2024","unstructured":"Li L, Jiang P, Hu W, Zou F, Li M, Rao T, Ruan Y, Yu W, Ning J, Cheng F (2024) AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2. J Transl Med 22(1):295. https:\/\/doi.org\/10.1186\/s12967-024-05099-6","journal-title":"J Transl Med"},{"key":"4527_CR21","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.3389\/fimmu.2019.02936","volume":"10","author":"SM Toor","year":"2019","unstructured":"Toor SM, Murshed K, Al-Dhaheri M, Khawar M, Abu Nada M, Elkord E (2019) Immune checkpoints in circulating and tumor-infiltrating CD4(+) T cell subsets in colorectal cancer patients. Front Immunol 10:2936. https:\/\/doi.org\/10.3389\/fimmu.2019.02936","journal-title":"Front Immunol"},{"issue":"6","key":"4527_CR22","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.3892\/ol.2020.11478","volume":"19","author":"MJ Nie","year":"2020","unstructured":"Nie MJ, Pan XT, Tao HY, Xu MJ, Liu SL, Sun W, Wu J, Zou X (2020) Clinical and prognostic significance of MYH11 in lung cancer. Oncol Lett 19(6):3899\u20133906. https:\/\/doi.org\/10.3892\/ol.2020.11478","journal-title":"Oncol Lett"},{"issue":"7967","key":"4527_CR23","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","volume":"618","author":"B Kruse","year":"2023","unstructured":"Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, van der Sluis TC, Hohn S, Antoranz A, Krone A, Fu Y, Yu D, Essand M, Geffers R, Mougiakakos D, Kahlfuss S, Kashkar H, Gaffal E, Bosisio FM, Bechter O, Rambow F, Marine JC, Kastenmuller W, Muller AJ, Tuting T (2023) CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours. Nature 618(7967):1033\u20131040. https:\/\/doi.org\/10.1038\/s41586-023-06199-x","journal-title":"Nature"},{"key":"4527_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081850","author":"SP Nunes","year":"2020","unstructured":"Nunes SP, Henrique R, Jeronimo C, Paramio JM (2020) DNA methylation as a therapeutic target for bladder cancer. Cells. https:\/\/doi.org\/10.3390\/cells9081850","journal-title":"Cells"},{"issue":"1","key":"4527_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13148-023-01534-5","volume":"15","author":"G Kerdivel","year":"2023","unstructured":"Kerdivel G, Amrouche F, Calmejane MA, Carallis F, Hamroune J, Hantel C, Bertherat J, Assie G, Boeva V (2023) DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape, contributing to the aggressiveness of adrenocortical carcinoma. Clin Epigenetics 15(1):121. https:\/\/doi.org\/10.1186\/s13148-023-01534-5","journal-title":"Clin Epigenetics"},{"issue":"18","key":"4527_CR26","doi-asserted-by":"publisher","first-page":"16311","DOI":"10.1007\/s00432-023-05390-x","volume":"149","author":"X Meng","year":"2023","unstructured":"Meng X, Song W, Zhou B, Liang M, Gao Y (2023) Prognostic and immune correlation analysis of mitochondrial autophagy and aging-related genes in lung adenocarcinoma. J Cancer Res Clin Oncol 149(18):16311\u201316335. https:\/\/doi.org\/10.1007\/s00432-023-05390-x","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"4527_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11912-018-0727-5","volume":"20","author":"DJ McConkey","year":"2018","unstructured":"McConkey DJ, Choi W (2018) Molecular subtypes of bladder cancer. Curr Oncol Rep 20(10):77. https:\/\/doi.org\/10.1007\/s11912-018-0727-5","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"4527_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"M Das","year":"2017","unstructured":"Das M, Zhu C, Kuchroo VK (2017) Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev 276(1):97\u2013111. https:\/\/doi.org\/10.1111\/imr.12520","journal-title":"Immunol Rev"},{"issue":"3","key":"4527_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK (2020) TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol 20(3):173\u2013185. https:\/\/doi.org\/10.1038\/s41577-019-0224-6","journal-title":"Nat Rev Immunol"},{"key":"4527_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.620705","volume":"12","author":"D Dai","year":"2021","unstructured":"Dai D, Xie L, Shui Y, Li J, Wei Q (2021) Identification of tumor microenvironment-related prognostic genes in sarcoma. Front Genet 12:620705. https:\/\/doi.org\/10.3389\/fgene.2021.620705","journal-title":"Front Genet"},{"issue":"1","key":"4527_CR31","doi-asserted-by":"publisher","first-page":"19695","DOI":"10.1038\/s41598-020-76688-w","volume":"10","author":"J Zhu","year":"2020","unstructured":"Zhu J, Wang H, Ma T, He Y, Shen M, Song W, Wang JJ, Shi JP, Wu MY, Liu C, Wang WJ, Huang YQ (2020) Identification of immune-related genes as prognostic factors in bladder cancer. Sci Rep 10(1):19695. https:\/\/doi.org\/10.1038\/s41598-020-76688-w","journal-title":"Sci Rep"},{"issue":"1","key":"4527_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13148-024-01633-x","volume":"16","author":"D Zhu","year":"2024","unstructured":"Zhu D, Zeng S, Su C, Li J, Xuan Y, Lin Y, Xu E, Fan Q (2024) The interaction between DNA methylation and tumor immune microenvironment: from the laboratory to clinical applications. Clin Epigenetics 16(1):24. https:\/\/doi.org\/10.1186\/s13148-024-01633-x","journal-title":"Clin Epigenetics"},{"issue":"7","key":"4527_CR33","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3724\/abbs.2022075","volume":"54","author":"L Wu","year":"2022","unstructured":"Wu L, Yang Z, Dai G, Fan B, Yuan J, Liu Y, Liu P, Ou Z (2022) SOX5 promotes cell growth and migration through modulating the DNMT1\/p21 pathway in bladder cancer. Acta Biochim Biophys Sin (Shanghai) 54(7):987\u2013998. https:\/\/doi.org\/10.3724\/abbs.2022075","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"3","key":"4527_CR34","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3892\/or.2018.6553","volume":"40","author":"H Zhang","year":"2018","unstructured":"Zhang H, Qi D, Li J, Peng T, Yang L, Yuan J, Zhang Y, Hu Y, Su J, Que B, Li M, Zhou G, Chen Y, Zhang W, Ji W (2018) A novel regulatory circuit of miR-152 and DNMT1 in human bladder cancer. Oncol Rep 40(3):1803\u20131812. https:\/\/doi.org\/10.3892\/or.2018.6553","journal-title":"Oncol Rep"},{"issue":"7","key":"4527_CR35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.pathol.2017.08.009","volume":"49","author":"SK Loo","year":"2017","unstructured":"Loo SK, Ch\u2019ng ES, Lawrie CH, Muruzabal MA, Gaafar A, Pomposo MP, Husin A, Md Salleh MS, Banham AH, Pedersen LM, Moller MB, Green TM, Wong KK (2017) DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. Pathology 49(7):731\u2013739. https:\/\/doi.org\/10.1016\/j.pathol.2017.08.009","journal-title":"Pathology"},{"issue":"12","key":"4527_CR36","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202301306R","volume":"37","author":"D Shao","year":"2023","unstructured":"Shao D, Liu C, Wang Y, Lin J, Cheng X, Han P, Li Z, Jian D, Nie J, Jiang M, Wei Y, Xing J, Guo Z, Wang W, Yi X, Tang H (2023) DNMT1 determines osteosarcoma cell resistance to apoptosis by associatively modulating DNA and mRNA cytosine-5 methylation. FASEB J 37(12):e23284. https:\/\/doi.org\/10.1096\/fj.202301306R","journal-title":"FASEB J"},{"issue":"3","key":"4527_CR37","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41418-019-0389-3","volume":"27","author":"H Liu","year":"2020","unstructured":"Liu H, Song Y, Qiu H, Liu Y, Luo K, Yi Y, Jiang G, Lu M, Zhang Z, Yin J, Zeng S, Chen X, Deng M, Jia X, Gu Y, Chen D, Zheng G, He Z (2020) Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. Cell Death Differ 27(3):966\u2013983. https:\/\/doi.org\/10.1038\/s41418-019-0389-3","journal-title":"Cell Death Differ"},{"issue":"5","key":"4527_CR38","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/mc.22319","volume":"55","author":"AP Lombard","year":"2016","unstructured":"Lombard AP, Mooso BA, Libertini SJ, Lim RM, Nakagawa RM, Vidallo KD, Costanzo NC, Ghosh PM, Mudryj M (2016) miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1. Mol Carcinog 55(5):757\u2013767. https:\/\/doi.org\/10.1002\/mc.22319","journal-title":"Mol Carcinog"},{"issue":"1","key":"4527_CR39","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41467-023-37807-z","volume":"14","author":"DJ Kim","year":"2023","unstructured":"Kim DJ, Anandh S, Null JL, Przanowski P, Bhatnagar S, Kumar P, Shelton SE, Grundy EE, Chiappinelli KB, Kamm RD, Barbie DA, Dudley AC (2023) Priming a vascular-selective cytokine response permits CD8(+) T-cell entry into tumors. Nat Commun 14(1):2122. https:\/\/doi.org\/10.1038\/s41467-023-37807-z","journal-title":"Nat Commun"},{"issue":"3","key":"4527_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1158\/0008-5472.CAN-23-1082","volume":"84","author":"H Tao","year":"2024","unstructured":"Tao H, Jin C, Zhou L, Deng Z, Li X, Dang W, Fan S, Li B, Ye F, Lu J, Kong X, Liu C, Luo C, Zhang Y (2024) PRMT1 inhibition activates the interferon pathway to potentiate antitumor immunity and enhance checkpoint blockade efficacy in melanoma. Cancer Res 84(3):419\u2013433. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1082","journal-title":"Cancer Res"},{"key":"4527_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109113","volume":"111","author":"SC Yang","year":"2022","unstructured":"Yang SC, Wang WY, Zhou JJ, Wu L, Zhang MJ, Yang QC, Deng WW, Sun ZJ (2022) Inhibition of DNMT1 potentiates antitumor immunity in oral squamous cell carcinoma. Int Immunopharmacol 111:109113. https:\/\/doi.org\/10.1016\/j.intimp.2022.109113","journal-title":"Int Immunopharmacol"},{"key":"4527_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12967-016-0840-x","volume":"14","author":"E Shin","year":"2016","unstructured":"Shin E, Lee Y, Koo JS (2016) Differential expression of the epigenetic methylation-related protein DNMT1 by breast cancer molecular subtype and stromal histology. J Transl Med 14:87. https:\/\/doi.org\/10.1186\/s12967-016-0840-x","journal-title":"J Transl Med"},{"issue":"5","key":"4527_CR43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, Yang B, Ding L (2020) Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B 10(5):723\u2013733. https:\/\/doi.org\/10.1016\/j.apsb.2019.09.006","journal-title":"Acta Pharm Sin B"},{"issue":"11","key":"4527_CR44","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/1078-0432.CCR-22-3642","volume":"29","author":"HJ Jang","year":"2023","unstructured":"Jang HJ, Hostetter G, Macfarlane AW, Madaj Z, Ross EA, Hinoue T, Kulchycki JR, Burgos RS, Tafseer M, Alpaugh RK, Schwebel CL, Kokate R, Geynisman DM, Zibelman MR, Ghatalia P, Nichols PW, Chung W, Madzo J, Hahn NM, Quinn DI, Issa JJ, Topper MJ, Baylin SB, Shen H, Campbell KS, Jones PA, Plimack ER (2023) A Phase II trial of guadecitabine plus atezolizumab in metastatic urothelial carcinoma progressing after initial immune checkpoint inhibitor therapy. Clin Cancer Res 29(11):2052\u20132065. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3642","journal-title":"Clin Cancer Res"},{"key":"4527_CR45","doi-asserted-by":"publisher","first-page":"1072651","DOI":"10.3389\/fphar.2022.1072651","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wang G, Li Y, Lei D, Xiang J, Ouyang L, Wang Y, Yang J (2022) Recent progress in DNA methyltransferase inhibitors as anticancer agents. Front Pharmacol 13:1072651. https:\/\/doi.org\/10.3389\/fphar.2022.1072651","journal-title":"Front Pharmacol"},{"issue":"8","key":"4527_CR46","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1158\/2326-6066.CIR-21-0802","volume":"10","author":"M Denis","year":"2022","unstructured":"Denis M, Grasselly C, Choffour PA, Wierinckx A, Mathe D, Chettab K, Tourette A, Talhi N, Bourguignon A, Birzele F, Kress E, Jordheim LP, Klein C, Matera EL, Dumontet C (2022) In Vivo syngeneic tumor models with acquired resistance to anti-PD-1\/PD-L1 therapies. Cancer Immunol Res 10(8):1013\u20131027. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0802","journal-title":"Cancer Immunol Res"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04527-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04527-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04527-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:34:08Z","timestamp":1759844048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04527-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4527"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04527-w","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Animal welfare and experimental procedures were approved by the Animal Ethics Committee of the Second Affiliated Hospital of Harbin Medical University and followed the guidelines for the care and use of laboratory animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each participant signed an informed consent form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}